timeframe (e.g. lifetime, current). When applying typical/atypical sub-phenotyping strategies an important aspect to consider may be the possible impact of antidepressant medications (AD), some of which may affect weight change and other metabolic disturbances(49). For the current study, previous results from NESDA point toward a reduced likelihood of AD impact. The AD classes more commonly used were not cross-sectionally associated with metabolic dysregulations(50) nor with 2-year trajectories of weight change(51). In another study(18) focusing on a subset of patients with current chronic MDD, AD used were similar across typical and atypical subtypes; moreover, the differential associations across subtypes of characteristics such as waist circumference, BMI, triglycerides and CRP was unchanged after adjustment for antidepressant use.
